Clinical Study

A Randomized Phase II Study Of Perioperative Mfolfirinox Versus Gemcitabine/Nab-Paclitaxel As Therapy For Resectable Pancreatic Adenocarcinoma.

Posted Date: Apr 5, 2018

  • Investigator: John Morris
  • Specialties: Gastroenterology, Hematology/Oncology, Oncology, Cancer, Surgical Oncology
  • Type of Study: Drug

to compare the effects of two different combinations of FDA-approved chemotherapy drugs. These two combinations are called mFOLFIRINOX (oxaliplatin, irinotecan, and fluorouracil) and gemcitabine plus nab-paclitaxel. These chemotherapy drugs will be given before and after surgery. The addition of these chemotherapy drugs before surgery is a new approach that is being tested in this study. This new approach could prevent your cancer from returning, but it could also cause side-effects. This study will allow the researchers to know if it is a good idea to treat pancreatic cancer with chemotherapy drugs before surgery

Criteria:

To Be Eligible For This Study, Patients Must Have Pancreatic Cancer That Can Be Removed By Surgery.

Keywords:

Pancreatic, S1505, Resectable, Cancer, Gastrointestinal

For More Information:

Uc Cancer Institute
513-584-7698
kastla@uc.edu